DrMedHealth Review
DrMedHealth's strongest dimension is the sign-up and app experience.
DrMedHealth: Ended its telehealth service — the site now offers AI health information only. We're not linking to it. Here are the top-rated GLP-1 providers we recommend instead.
See our top-rated GLP-1 providers →DrMedHealth was a US telehealth platform that prescribed compounded semaglutide and tirzepatide. It has ended that service: drmedhealth.com now hosts AI health-information tools, and its terms say it no longer sells products or prescribes medication. Existing patients are pointed to a separate patient portal, CareGLP.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Vetted alternatives to DrMedHealth
altRX
Best for: low-cost compounded GLP-1s with brand-name Zepbound, Wegovy and Ozempic as options
Editorial score · methodology
RxSpan MD
Best for: physician-led, pharmacy-transparent compounded GLP-1 with brand-name options
Editorial score · methodology
Luvo Health
Best for: compounded and brand GLP-1s, oral tablets and microdosing on one public price list
Editorial score · methodology
DrMedHealth at a glance
- Type
- GLP-1 telehealth provider
- FDA status
- 1 FDA warning letter on record — see below
How we scored DrMedHealth
Each dimension is scored algorithmically from DrMedHealth’s real pricing, drugs offered, verification status, and disclosed inclusions — using the same six-dimension framework we apply to every provider.
Value25%
7.5/10DrMedHealth no longer sells GLP-1 treatment, so no current price applies.
Effectiveness25%
6.9/10DrMedHealth's offering is not built around the GLP-1 molecules with the strongest weight-loss trial evidence — weigh the clinical support carefully.
User Experience15%
8.3/10Online intake and platform experience; 3 platform features disclosed.
Trust & Safety15%
6.4/10Core details confirmed by our editors; an FDA warning letter is on file (see flag above).
Accessibility10%
7.5/10DrMedHealth's exact state footprint isn't published — confirm coverage in your state before signing up.
Support10%
7.3/10DrMedHealth provides standard clinician follow-up; no extended coaching or community program is disclosed.
Each checked against the provider’s own site.
Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →
How we verified this DrMedHealth review
Last checked October 2026- Checked the FDA warning-letter database for enforcement actions
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records — see the sources below. Editorial confidence in this data: medium.
What we checked
- FDA warning-letter register
- An active letter is on file for this provider — see below
What we like
- Former patients are told where to manage an active prescription (the CareGLP portal)
Watch-outs
- No longer prescribes GLP-1s or sells any medication
- Former GLP-1 pages now show an AI health-information site
- Received an FDA warning letter in June 2026 over its GLP-1 marketing
DrMedHealth no longer runs a telehealth clinic
If you came here looking for DrMedHealth's compounded semaglutide and tirzepatide program, it has ended. The drmedhealth.com address now hosts AI health-information tools: a health assistant, a provider search and condition overviews. Its old GLP-1 pages show that same information site, with no prices, no intake and no way to order.
This is not a page that happened to fail to load. DrMedHealth's own legal page says it does not sell any product, prescribe or dispense any medication, or provide medical care, and it refers to the clinic as its former telehealth service. That leaves no DrMedHealth program for us to price or rank.
What to do if you were a patient
The legal page tells patients with an active prescription to manage that care through their CareGLP patient portal, or to email DrMedHealth support with questions. Do that before your current supply runs out. A GLP-1 dose should be continued or adjusted on clinical advice, not interrupted because a provider stopped trading. If your medication label names a pharmacy, keep that information handy, because the dispensing pharmacy is a separate business from the platform that arranged your visits.
One more thing worth knowing before you move your care: in June 2026 the FDA sent the company behind DrMedHealth a warning letter about its GLP-1 marketing. Our FDA warning letter tracker lists it alongside letters sent to other telehealth sellers.
Where to look instead
The alternatives listed on this page are all currently operating and carry current prices. You can also start from our semaglutide provider rankings and compare what each provider includes as well as what it charges, using the factors in our scoring methodology.
Bottom line
DrMedHealth has closed its GLP-1 telehealth service, and the name now belongs to an AI health-information site. We keep this page up so people searching for DrMedHealth get a clear answer rather than a dead link. It is excluded from our rankings and carries no outbound link.
The Bottom Line
DrMedHealth's strongest dimension is the sign-up and app experience.
DrMedHealth might not be your best fit if…
We rank editorially, so here’s where a different provider we track may serve you better.
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Regulatory notice
DrMedHealth received an FDA warning letter dated June 8, 2026
The letter concerns false & misleading claims/misbranded (telehealth). FDA warning letters are public regulatory communications and do not, on their own, constitute a finding of illegal activity — companies often respond with corrective action.
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this DrMedHealth review:
Sources & methodology — as of October 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.